Health accreditation leader TEMOS International marks strategic expansion into India

IMT News Desk
IMT News Desk
· 2 min read

The organisation has formalised strategic collaborations through Memoranda of Understanding with SEPC, CAHO, Institution of Fire Engineers and AHPI

Global healthcare accreditation leader TEMOS International has successfully concluded its soft launch in New Delhi, marking a pivotal moment in the organization’s expansion into the Indian healthcare ecosystem. The strategic roundtable convened quality-driven healthcare institutions, TEMOS-approved consultants, assessors, Advisory Panel members, regional partner organisations, and Dr Claudia Mika, Founder and CEO, TEMOS International.

The New Delhi soft launch underscores TEMOS International’s commitment to strengthening India’s position as a destination for medical value travel while building a globally aligned, patient-centric, and trust-based healthcare ecosystem. The organisation has formalised strategic collaborations through Memoranda of Understanding with the Service Export Promotion Council (SEPC), the Confederation of All Healthcare Providers India (CAHO), the Institution of Fire Engineers, and the Association of Healthcare Providers India (AHPI), creating a foundation for knowledge sharing, capacity building, and the
advancement of medical tourism conferences and events across the nation.

In another development, Smriti Healthcare, a newly incorporated specialised medical chain dedicated to oncology and reproductive medicine (IVF), has officially signed a Memorandum of Understanding with TEMOS International to become the organisation’s Regional Partner for Uttar Pradesh. Headquartered in Lucknow with operational centres in Raebareli and expansion plans across the state, Smriti Healthcare’s partnership reflects a strategic commitment to international accreditation standards. By integrating TEMOS’ rigorous assessment frameworks, the organisation positions itself as a globally benchmarked institution capable of delivering world-class care while maintaining the patient-
centric approach that defines the TEMOS accreditation model.

Dr Mika mentioned, “India’s medical tourism potential can only be realised through meaningful collaboration, strong governance, and global benchmarking. TEMOS International remains open and committed to working with Indian stakeholders to
build a trusted and sustainable medical value travel ecosystem. We don’t just treat; we heal with science and lead with ethics. Join us on our journey to elevate healthcare for society at large.”

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk